Immune checkpoint inhibitor-induced granulomatosis with polyangiitis

Rheumatology (Oxford). 2021 Jun 18;60(6):e190-e191. doi: 10.1093/rheumatology/keaa818.

Authors

Whitney Hung¹, Ina Cusnir², Syed Habib³, Michael Smylie⁴, Kim Solez⁵, Elaine Yacyshyn⁶

Affiliations

¹ Department of Medicine, University of Alberta, Edmonton, Canada.
² Department of Rheumatology, University of Calgary, Calgary, Canada.
³ Department of Nephrology, University of Alberta, Edmonton, Alberta, Canada.
⁴ Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
⁵ Department of Pathology, University of Alberta, Edmonton, Alberta, Canada.
⁶ Department of Rheumatology, University of Alberta, Edmonton, Alberta, Canada.

PMID: 33367837
DOI: 10.1093/rheumatology/keaa818

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Diabetes Mellitus / chemically induced
Female
Glomerulonephritis / etiology
Glucocorticoids / adverse effects
Glucocorticoids / therapeutic use
Granulomatosis with Polyangiitis / chemically induced*
Granulomatosis with Polyangiitis / pathology
Humans
Immune Checkpoint Inhibitors / adverse effects*
Ipilimumab / adverse effects*
Melanoma / drug therapy*
Melanoma / pathology
Methylprednisolone / adverse effects
Methylprednisolone / therapeutic use
Neoplasm Recurrence, Local / drug therapy*
Nivolumab / adverse effects*
Renal Insufficiency, Chronic / etiology
Rituximab / therapeutic use
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

Glucocorticoids
Immune Checkpoint Inhibitors
Ipilimumab
Nivolumab
Rituximab
Methylprednisolone

Associated data

ClinicalTrials.gov/NCT02108860